ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on March 28, 2023, at 11:00 a.m. Eastern to discuss its 2022 financial results. CEO Ted Karkus will host the call, which will include a Q&A session.
Participants can register for the call via a provided link, and dial-in options are available for those without internet access. A replay will be available shortly after the call.
ProPhase specializes in diagnostics, genomics, and biotech, leveraging CLIA lab services for genome sequencing, and operates a contract manufacturing subsidiary, Pharmaloz.
- Scheduled conference call for March 28, 2023, provides transparency on financial performance.
- Focus on diagnostics and genomics indicates growth potential in healthcare.
- None.
GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Tuesday, March 28, 2023, at 11:00 a.m. Eastern time to discuss its results for the year ended December 31, 2022. A press release detailing these results will be issued prior to the call.
ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period.
To access the call, please use the following information:
| Date: | Tuesday, March 28, 2023 |
| Time: | 11:00 a.m. Eastern time, 8:00 a.m. Pacific time |
Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10176786/f8a78067aa
Please note that registered participants will receive their dial in number upon registration. Pre-registration required fields of information include: name, phone, company, email.
Those without internet access or unable to pre-register may dial in to the conference call by calling:
| Toll free dial in number: | 1-866-777-2509 |
| International dial in number: | 1-412-317-5413 |
Please call the conference telephone number 5-10 minutes prior to the start time. Please ask to be joined into the ProPhase Labs, Inc. conference call. An operator will register your name, phone and organization.
The conference call will be broadcast live and available for replay at https://event.choruscall.com/mediaframe/webcast.html?webcastid=Fg5WDKxb and via the investor relations section of the Company's website at www.ProPhaseLabs.com.
A replay of the conference call will be available two hours from when the call ends.
| Toll-free replay number: | 1-877-344-7529 |
| International replay number: | 1-412-317-0088 |
| Replay Access Code: | 7800122 |
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a growth oriented and diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing. The Company also operates Pharmaloz, a rapidly growing contract manufacturing subsidiary, and offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores throughout the country.
ProPhase Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen tests to broaden its COVID-19 testing beyond RT-PCR testing. The Company has announced plans for the expansion of the lab to include traditional clinical testing and genomics sequencing.
Nebula Genomics, a rapidly growing and wholly owned subsidiary of ProPhase, focuses on genomics sequencing and testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic sequencing may help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. The Company currently offers Nebula Genomics whole genome sequencing products direct-to-consumer online, with plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.
ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds. Licensed compounds currently include Equivir (OTC/dietary supplement) and Equivir G (Rx), two broad based anti-virals, and Linebacker LB-1 and LB-2, two small molecule PIM kinase inhibitors. The Company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co- therapy. The Company also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test and related IP assets. The BE-Smart test remains under validation as a LDT. The test is focused on the early detection of esophageal cancer and is intended to provide health care providers and patients with data to help determine treatment options.
ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Pharmaloz contract manufacturing subsidiary. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.
For more information, visit www.ProPhaseLabs.com.
ProPhase Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
ProPhase Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
FAQ
When is ProPhase Labs' 2022 financial results conference call?
Who will host the ProPhase Labs conference call?
How can I access the ProPhase Labs conference call?
What is the focus of ProPhase Labs as mentioned in the press release?
